These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33796451)

  • 1. Analysis of Gut Microbiome Using Explainable Machine Learning Predicts Risk of Diarrhea Associated With Tyrosine Kinase Inhibitor Neratinib: A Pilot Study.
    Wong CW; Yost SE; Lee JS; Gillece JD; Folkerts M; Reining L; Highlander SK; Eftekhari Z; Mortimer J; Yuan Y
    Front Oncol; 2021; 11():604584. PubMed ID: 33796451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
    Barcenas CH; Hurvitz SA; Di Palma JA; Bose R; Chien AJ; Iannotti N; Marx G; Brufsky A; Litvak A; Ibrahim E; Alvarez RH; Ruiz-Borrego M; Chan N; Manalo Y; Kellum A; Trudeau M; Thirlwell M; Garcia Saenz J; Hunt D; Bryce R; McCulloch L; Rugo HS; Tripathy D; Chan A;
    Ann Oncol; 2020 Sep; 31(9):1223-1230. PubMed ID: 32464281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
    Chan A; Ruiz-Borrego M; Marx G; Chien AJ; Rugo HS; Brufsky A; Thirlwell M; Trudeau M; Bose R; García-Sáenz JA; Egle D; Pistilli B; Wassermann J; Cheong KA; Schnappauf B; Semsek D; Singer CF; Foruzan N; DiPrimeo D; McCulloch L; Hurvitz SA; Barcenas CH
    Breast; 2023 Feb; 67():94-101. PubMed ID: 36702070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.
    Secombe KR; Ball IA; Shirren J; Wignall AD; Keefe DM; Bowen JM
    Breast Cancer; 2021 Jan; 28(1):99-109. PubMed ID: 32683606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats.
    Secombe KR; Ball IA; Wignall AD; Bateman E; Keefe DM; Bowen JM
    Neoplasia; 2022 Aug; 30():100806. PubMed ID: 35561424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
    Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
    Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
    Mortimer J; Di Palma J; Schmid K; Ye Y; Jahanzeb M
    Breast Cancer Res; 2019 Feb; 21(1):32. PubMed ID: 30813966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
    Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
    JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
    Jacob S; Johnson M; Roque B; Quintal L; Rugo HS; Melisko M; Chien AJ
    Clin Breast Cancer; 2023 Oct; 23(7):721-728. PubMed ID: 37474374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of gastrointestinal complications in breast cancer patients treated with neratinib: a meta-analysis.
    Jiang N; Song XW; Lin JJ; Wang ZY; Zhang BN; Li A; Yan RY; Yan HF; Fu XY; Zhou JL; Li CL; Cui Y
    Expert Opin Drug Saf; 2017 Oct; 16(10):1111-1119. PubMed ID: 28766379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials.
    Tao Z; Li SX; Shen K; Zhao Y; Zeng H; Ma X
    Clin Drug Investig; 2019 Jan; 39(1):27-43. PubMed ID: 30370488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature.
    Kruse ML; Kang IM; Bagegni NA; Howell WT; Moore HCF; Bedell CH; Stokoe CT
    Oncol Ther; 2022 Jun; 10(1):279-289. PubMed ID: 34800263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Chia SKL; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Gokmen E; Bashford A; Ruiz Borrego M; Kim SB; Jakobsen EH; Ciceniene A; Inoue K; Overkamp F; Heijns JB; Armstrong AC; Link JS; Joy AA; Bryce R; Wong A; Moran S; Yao B; Xu F; Auerbach A; Buyse M; Chan A;
    Lancet Oncol; 2017 Dec; 18(12):1688-1700. PubMed ID: 29146401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neratinib for HER2-positive breast cancer with an overlooked option.
    Guo L; Shao W; Zhou C; Yang H; Yang L; Cai Q; Wang J; Shi Y; Huang L; Zhang J
    Mol Med; 2023 Oct; 29(1):134. PubMed ID: 37803271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
    Piha-Paul SA; Tseng C; Tran HT; Gao M; Karp DD; Subbiah V; Tsimberidou AM; Kawedia JD; Fu S; Pant S; Yap TA; Morris VK; Kee BK; Blum Murphy M; Lim J; Meric-Bernstam F
    Cancer Chemother Pharmacol; 2023 Aug; 92(2):107-118. PubMed ID: 37314501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.
    Freedman RA; Gelman RS; Agar NYR; Santagata S; Randall EC; Gimenez-Cassina Lopez B; Connolly RM; Dunn IF; Van Poznak CH; Anders CK; Melisko ME; Silvestri K; Cotter CM; Componeschi KP; Marte JM; Moy B; Blackwell KL; Puhalla SL; Ibrahim N; Moynihan TJ; Nangia J; Tung N; Burns R; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU;
    Clin Breast Cancer; 2020 Apr; 20(2):145-151.e2. PubMed ID: 31558424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Explainable artificial intelligence for microbiome data analysis in colorectal cancer biomarker identification.
    Novielli P; Romano D; Magarelli M; Bitonto PD; Diacono D; Chiatante A; Lopalco G; Sabella D; Venerito V; Filannino P; Bellotti R; De Angelis M; Iannone F; Tangaro S
    Front Microbiol; 2024; 15():1348974. PubMed ID: 38426064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
    Blackwell KL; Zaman K; Qin S; Tkaczuk KHR; Campone M; Hunt D; Bryce R; Goldstein LJ;
    Clin Breast Cancer; 2019 Apr; 19(2):97-104.e4. PubMed ID: 30655172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.